The purpose of our research was to test the therapeutic efficacy of the acaricide «Simparica®» in combination with the biostimulator «Catosal» and the hepatoprotector «Tioprotectin» for demodicosis in dogs in the conditions of veterinary clinics in the Kamianets-Podilskyi, Ukraine. The study has been performed on dogs of different genders, ages and breeds that had a generalized form of demodicosis (affected at least 6 areas on the body of animals), to test the effectiveness of this drug in different treatment schemes. Acarological studies of scrapings from the skin of experimental animals for the presence of live or dead mites Demodex canis or their eggs have been carried out by the vital method according to D.O. Pryselkova. As a result of the conducted researches the choice of acaricidal drugs and development of complex therapeutic measures for demodicosis of dogs has been experimentally substantiated. The drug «Simparica®» has proved to be quite effective against demodicosis of dogs, even with a single use. The dependence of the effectiveness of the use of prolonged acaricide «Simparica®» on clinical forms of demodicosis has been shown. The absolute therapeutic effect of acaricide is obtained in the scaly form of demodicosis. However, in pustular and mixed clinical forms of demodicosis, its effectiveness decreased to 71.4 and 57.1%, respectively. In combination with the drug of pathogenetic therapy «Catosal» for pustular and mixed forms of demodicosis, the therapeutic efficacy of the drug «Simparica®» increases to 85.7%. When added to the scheme of hepatoprotector “Thioprotectin”, it is possible to achieve 100% therapeutic effect in pustular forms of demodicosis. However, in severe mixed form of demodicosis, the effectiveness was not absolute and was only 85.7%. In case of generalized demodicosis of dogs, regardless of clinical forms, it is recommended to use the acaricide «Simparica®» in combination with the drug «Catosal» and in the combination of «Catosal» and «Thioprotectin».
Background and Aim: Mastitis, an inflammation of the mammary gland, is an ongoing problem in dairy herds. In this study, we determined the sensitivity of Staphylococcus aureus cultures of different biological origins to commercial bacteriophages and phages of S. aureus var. bovis which were isolated on dairy farms, to create a drug for the treatment of mastitis in cows. Materials and Methods: We used cultures of S. aureus isolated from different habitats, and other types of staphylococci isolated on dairy farms. As antibacterial agents, the commercially available bacteriophages staphylococcal bacteriophage and Intestifag and field strains of phages Phage SAvB07, Phage SAvB08, Phage SAvB12, and Phage SAvB14 were used. Evaluation of their lytic properties was performed using the drip method. Results: The drug Intestifag lysed cultures isolated from human habitats and archival strains of S. aureus No.209-P and S. aureus (ATCC 25923) in 91.8%–100% of cases. Staphylococcal bacteriophage killed 3.6 times fewer cultures of S. aureus isolated from humans than Intestifag and did not affect the growth of archival strains. Neither drug lysed cultures isolated from cows or cultures isolated from dairy products sold in agri-food markets. Phage SAvB14 lysed 92.7±8.3% of S. aureus isolated from the mammary glands of cows and 69.2±6.4% of cultures isolated from dairy products sold in agri-food markets. Phage SAvB12, Phage SAvB08, and Phage SAvB07 lysed 1.2-1.7 times fewer cultures isolated from the mammary glands of cows and 6-18 times fewer cultures isolated from dairy products, compared with Phage SAvB14. Phages of S. aureus var. bovis can infect staphylococcal species such as Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus saprophyticus, and Staphylococcus xylosus. The widest range of hosts was found for Phage SAvB14, which indicates its polyvalence. Conclusion: The biological origin of staphylococcal strains must be considered when developing effective phage therapy. Phage SAvB14 appears to be a good candidate for the development of a drug for the treatment of mastitis in cows.
In practical terms, the idea of using an artificial magnetic field is of particular interest, which corresponds in its physical characteristics to the geomagnetic field of the Earth to combat the negative effects of hypogeomagnetic field. Further development of this idea is associated with the use and selection of hypo-, hypermagnetic fields acting on the body with experimental pathology. In this regard, the issue of influence of different duration of irradiation with an alternating pulsed electromagnetic field of ultra-low frequency (APEMF ULF) on the indicators that characterize metabolic processes in the body is insufficiently clarified. Therefore, the aim of research has been to study the effect of alternating pulsed electromagnetic field of ultra-low frequency on protein content and protein metabolism in the body of experimental chickens of the Dominant D959 cross. For this purpose, four experimental and control groups of 120-day-old chickens have been formed – 20 heads in each. The poultry has been kept in a specially equipped room with an alternating pulsed electromagnetic field of ultra-low frequency. The total protein content has been determined by the biuret method; protein fractions (albumins, globulins: alpha-1, alpha-2, beta, gamma) – by diffuse polyacrylamide gel (PAAG) electrophoresis; the content of creatinine, urea and uric acid has been performed by spectrophotometry using standard techniques. According to the results of research, it has been established that by selecting different regimens and duration of action of APEMF ULF, it is possible to influence protein metabolism in the body of chickens. Thus, on the 80th day of continuous irradiation of experimental chickens with APEMF ULF, regardless of the level of protein in the diet, in their blood revealed an increase in total protein, the relative content of globulin fraction mainly due to γ-globulins, and an increase in creatinine, urea and uric acids. When the period of continuous irradiation has been increased to 5 months, a negative effect on protein metabolism has been revealed, which has been manifested by a decrease in total protein content, relative albumin content, decrease in creatinine, urea and uric acid in the serum of experimental chickens. The combination of long-term (for 150 days) daily 60 minutes with weekly intervals of irradiation of chickens with APEMF ULF and their feeding with a 15% increase in protein levels in the diet caused a stimulating effect on protein metabolism and resistance of experimental chickens, with increasing, the relative content of globulins due to the γ-globulin fraction, as well as the main indicators of protein metabolism – creatinine, urea, uric acid. Key words: electromagnetic influence, chicken of Dominant D959 cross, total protein, protein fractions, creatinine, urea, uric acid.
Demodicosis is one of the most common diseases in dogs. We have analyzed the epizootological features of the course of demodectic invasion in dogs. In the process of research, territorial, age, breed, sex, seasonal features of the distribution of canine demodicosis, clinical forms of its manifestation were studied. When making a diagnosis, the generally accepted laboratory diagnostic method was used. In the conditions of the Kamenetz-Podolsk region, the share of demodicosis of all pathologies of the skin of dogs is 24.6%. Clinically, 69.9% of the animals had local demodicosis, and its most common forms were scaly (35.4%), mixed (21.2%) and pustular (18.6%). The highest morbidity rate was observed in female short-haired breeds (Bulldog, Rottweiler and Pug) at the age of 7-12 months, there were two peaks in the incidence of dogs in March - 31.1% and in October-November (37.8-34.1%).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.